Planning Clinical Research

This book teaches how to choose the best design for your question. Planning a clinical study is much more than deciding on the basic study design. Who will you be studying? How do you plan to recruit your study participants? How do you plan to retain them in the study? What data do you plan to collect? How will you obtain this data? How will you minimize bias? All these decisions must be consistent with the ethical considerations of studying people.

Drawing on their many years working in clinical research, Robert A. Parker and Nancy Greene Berman guide readers through the essential elements of study planning to help get them started. The authors offer numerous examples to illustrate the key decisions needed, describing what works and what does not work, and why. Written specifically for junior investigators beginning their research careers, this guide will also be useful to senior investigators needing to review specific topics.

Dr. Robert A. Parker has been a consulting biostatistician for nearly 40 years. He has worked in academia, medicine, industry (a Top 25 global pharmaceutical company), and government (World Health Organization; US Centers for Disease Control). In industry, he was the arbiter of statistical methods for more than 100 statisticians at the company that employed him. Having worked with junior investigators for most of his professional life, he is dedicated to mentoring the next generation of medical researchers. This book reflects his passion to train junior investigators in the art of clinical research.

Dr. Nancy Greene Berman has been a consulting biostatistician for more than 35 years. She has worked in private consulting for NIH and other government studies. In Los Angeles, she was chairperson of the annual Statistical Workshop and treasurer for the Southern California Statistical Association. As the General Clinical Research Center (GCRC) statistician and consultant at the Harbor-UCLA Medical Center, she worked with both junior and senior investigators developing protocols for clinical studies. Doing this work she identified the need for a book that would provide details of clinical design in an accessible format for all investigators. This book is intended to fulfill that need.
Planning Clinical Research

Robert A. Parker
Harvard Medical School

Nancy Greene Berman
School of Public Health, UCLA Los Angeles
To Laurie, for everything (R.A.P)

To my family (N.G.B)
# Contents

*Preface*  
*Acknowledgments*

## PART I  INTRODUCTION

1. Questions before Starting on the Details  
   1.1 What Are the Broad Issues?  
   1.2 Question 1: Why Do You Want to Do Research?  
   1.3 Question 2: What Is Your Question?  
   1.4 Question 3: Why Does Answering This Question Matter?  
   1.5 Question 4: Why Are You the Person to Answer the Question?  
   1.6 Question 5: How Will You Know Whether You Have Answered Your Question?  
   1.7 Ethical Issues  

## Key Points

## References

2. Ethics  
   2.1 How Ethical Guidelines Developed  
      2.1.1 International Codes  
      2.1.2 The United States  
   2.2 Principles of Ethical Practice  
      2.2.1 Social and Clinical Value  
      2.2.2 Scientific Validity  
      2.2.3 Fair Subject Selection  
      2.2.4 Favorable Risk-Benefit Ratio  
      2.2.5 Independent Review
## Contents

2.2.6 Informed Consent 22  
2.2.7 Respect for Potential and Enrolled Subjects 22  
2.3 The Institutional Review Board (IRB) 23  
2.4 The Data Safety and Monitoring Board (DSMB) 25  
2.5 Resources for Further Reading 26  
Key Points 26  

3. Informed Consent 28  
3.1 The Consent Process 28  
3.1.1 The Consent Document 29  
3.1.2 The Consent Interview 34  
3.2 The Authorization Form for Protecting Data 36  
3.3 Coercion and Undue Influence 37  
3.4 Special Populations 38  
3.4.1 Children 38  
3.4.2 Persons Unable to Understand and Agree to the Study 39  
3.4.3 Speakers of Other Languages 40  
3.4.4 Pregnant Women, Fetuses or Neonates 40  
3.4.5 Prisoners 41  
3.5 Use and Retention of Tissue Samples 41  
3.6 Situations When Consent Is Not Required or May Be Postponed 42  
3.7 Ethical Issues 42  
Key Points 43  

## PART II STUDY DESIGNS 45  

4. Overview of Study Designs 47  
4.1 Interventional Designs 47  
4.2 Designs for Observational Studies 49  
4.3 Clinical Trials 52  
4.4 Different Questions May Represent Different Designs in the Same Study 53  
4.5 How You Frame the Question Affects the Types of Studies Possible 54  
4.6 Advantages of Interventional Studies 57  
4.7 Difficulties of Interventional Studies 58  
4.8 Ethical Issues 59  
Key Points 61
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Designs for Interventional Studies</td>
<td>62</td>
</tr>
<tr>
<td>5.1 Summary of Interventional Designs</td>
<td>62</td>
</tr>
<tr>
<td>5.2 The Question Being Studied</td>
<td>63</td>
</tr>
<tr>
<td>5.3 Studies in Which All Participants Receive the Intervention</td>
<td>64</td>
</tr>
<tr>
<td>5.3.1 Single Group of Participants</td>
<td>64</td>
</tr>
<tr>
<td>5.3.2 More Than One Group of Participants</td>
<td>66</td>
</tr>
<tr>
<td>5.4 Studies in Which Some Participants Receive the Intervention and Some Do Not: Parallel Group Studies</td>
<td>68</td>
</tr>
<tr>
<td>5.5 Studies in Which All Participants Are Studied with and without the Intervention</td>
<td>74</td>
</tr>
<tr>
<td>5.5.1 Comparison within a Single Participant with Intervention in Random Order (Crossover Study)</td>
<td>74</td>
</tr>
<tr>
<td>5.5.2 Comparison within a Single Participant with Intervention in Fixed Order (Pre-Post Study)</td>
<td>77</td>
</tr>
<tr>
<td>5.6 Ethical Issues</td>
<td>80</td>
</tr>
<tr>
<td>Key Points</td>
<td>81</td>
</tr>
<tr>
<td>6. Cohort Studies</td>
<td>82</td>
</tr>
<tr>
<td>6.1 Basic Designs</td>
<td>82</td>
</tr>
<tr>
<td>6.2 Advantages of Cohort Studies Compared to Interventional Studies</td>
<td>86</td>
</tr>
<tr>
<td>6.3 Disadvantages of Cohort Studies Compared to Interventional Studies</td>
<td>87</td>
</tr>
<tr>
<td>6.4 Prospective versus Retrospective Cohort Studies</td>
<td>90</td>
</tr>
<tr>
<td>6.5 Ethical Issues</td>
<td>92</td>
</tr>
<tr>
<td>Key Points</td>
<td>93</td>
</tr>
<tr>
<td>7. Case-Control Studies</td>
<td>95</td>
</tr>
<tr>
<td>7.1 Basic Design</td>
<td>95</td>
</tr>
<tr>
<td>7.2 Selecting Participants</td>
<td>97</td>
</tr>
<tr>
<td>7.3 Matching</td>
<td>98</td>
</tr>
<tr>
<td>7.4 Nested Case-Control Studies</td>
<td>99</td>
</tr>
<tr>
<td>7.5 Advantages and Disadvantages of Case-Control Studies</td>
<td>100</td>
</tr>
<tr>
<td>7.6 Ethical Issues</td>
<td>102</td>
</tr>
<tr>
<td>Key Points</td>
<td>102</td>
</tr>
<tr>
<td>8. Cross-Sectional Studies</td>
<td>104</td>
</tr>
<tr>
<td>8.1 Fundamental Features</td>
<td>104</td>
</tr>
<tr>
<td>8.2 Examples of Cross-Sectional Studies</td>
<td>105</td>
</tr>
</tbody>
</table>
# Contents

8.3 Some Common Problems in Cross-Sectional Studies  
8.4 Ethical Issues  
Key Points

9. Record Reviews  
9.1 Data Availability and Quality  
9.1.1 Data Availability  
9.1.2 Data Quality  
9.1.3 What Can Be Done about Data Problems?  
9.2 Examples of Record Reviews  
9.3 Ethical Issues  
Key Points

10. Selecting a Design  
10.1 A Range of Designs  
10.2 Interventional or Observational Study?  
10.2.1 Is an Interventional Study Ethical?  
10.2.2 Is an Interventional Study Practical?  
10.3 Selecting an Interventional Study Design  
10.3.1 Randomized or Non-Randomized Study?  
10.3.2 Parallel Group or Crossover Study?  
10.4 Observational Studies  
10.4.1 Case-Control or Cohort Study?  
10.4.2 Cohort Study: Retrospective or Prospective?  
10.5 Example of Developing a Design  
10.6 Ethical Issues  
Key Points

PART III CORE CONCEPTS APPLICABLE TO ALL STUDY DESIGNS

11. Generalizability and Validity  
11.1 The Population  
11.2 Study Methods  
11.2.1 Treatment and Treatment Monitoring  
11.2.2 Assessment Methods  
11.3 Validity  
11.4 Ethical Issues  
Key Points
Contents

12. Study Population 147
   12.1 The Target Population and the Study Pool 147
   12.2 The Eligible Group 148
   12.3 The Study Group 157
   12.4 Ethical Issues 158
   Key Points 159

13. Getting and Keeping Participants 161
   13.1 Recruiting the Right Number of Participants 161
   13.2 Recruitment and Retention Is Part of Planning 163
   13.3 Locating and Recruiting Participants 164
   13.4 Retention and Adherence 168
   13.5 Use of the Internet 171
   13.6 Ethical Issues 172
   Key Points 174

14. Study Data: How Variables Are Used 175
   14.1 Types of Variables 175
   14.2 Role of Variables in an Interventional Study 176
   14.3 Role of Variables in Observational Studies 181
   14.4 Measuring Variables 183
   14.5 Recoding Data 184
   14.6 Storing Data 184
   14.7 Ethical Issues 185
   Key Points 186

15. Study Data: Endpoints 187
   15.1 Defining the Outcome Variables 187
   15.2 Derived Outcomes 190
   15.3 Time-Related Outcomes 192
   15.4 Ethical Issues 194
   Key Points 195

16. Study Data: Predictor and Confounding Variables 196
   16.1 Predictor Variables 196
   16.2 Confounding Variables 198
   16.3 Predictors versus Confounders 199
   16.4 Ethical Issues 200
   Key Points 201
17. Bias
  17.1 Common Sources of Bias
    17.1.1 Prognostic Bias
    17.1.2 Selection Bias
    17.1.3 Participant Bias
    17.1.4 Recall Bias
    17.1.5 Bias Due to the Learning Effect
    17.1.6 Care Provider Bias
    17.1.7 Assessor (Rater) Bias
    17.1.8 Laboratory Bias
    17.1.9 Analysis Bias
    17.1.10 Interpretation Bias
    17.1.11 Publication Bias
  17.2 Non-Differential Bias
  17.3 Ethical Issues
  Key Points

18. Avoiding Bias
  18.1 Selection of Study Population
  18.2 Randomization
  18.3 Blinding
  18.4 Assessment Methods and Training
  18.5 Data Monitoring during the Study
  18.6 Ethical Issues
  Key Points

PART IV ADDITIONAL CONCEPTS FOR INTERVENTIONAL STUDIES

19. Describing the Intervention
  19.1 Problems in Describing an Intervention
  19.2 Determining the Control Intervention
  19.3 Describing the Control Intervention
  19.4 Ethical Issues
  Key Points
## Contents

### Chapter 20: Randomization: What and Why

20.1 What Is Randomization? 237  
20.2 Why Randomize? 240  
20.3 Why Randomize Individuals? 242  
20.4 Ethical Issues 243  
   Key Points 244

### Chapter 21: Techniques for Randomization

21.1 Requirements for a Valid Randomized Study 245  
21.2 Creating a Randomization Schedule 246  
21.3 Adding Special Features to the Randomization Schedule 249  
   21.3.1 Stratification 250  
   21.3.2 Blocking 252  
   21.3.3 Benefits and Pitfalls of Stratification and Blocking 254  
21.4 Unbalanced Randomization 255  
21.5 Ethical Issues 256  
   Key Points 257

### Chapter 22: Blinding in Interventional Studies

22.1 Why Blinding Is Used 258  
22.2 The Hierarchy of Blinding 259  
   22.2.1 Double-Blind Studies 260  
   22.2.2 Complete Blinding 261  
   22.2.3 Single-Blind Studies 262  
   22.2.4 Open-Label Studies 264  
   22.2.5 Multiple Levels of Blinding 266  
22.3 Monitoring Safety and Breaking the Blind 266  
22.4 When the Blind Is Broken 267  
22.5 Ethical Issues 268  
   Key Points 269

### Chapter 23: Techniques to Blind Interventional Studies

23.1 Masking the Intervention 270  
   23.1.1 Masking a Pharmaceutical Intervention 270  
   23.1.2 Maintaining the Mask When Dosage Levels Change 272  
   23.1.3 Masking a Non-Pharmaceutical Intervention 273
### Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>23.1.4</td>
<td>Masking Laboratory Staff</td>
<td>274</td>
</tr>
<tr>
<td>23.1.5</td>
<td>Masking Data Management Staff</td>
<td>275</td>
</tr>
<tr>
<td>23.2</td>
<td>Providing the Intervention in Blinded Studies</td>
<td>275</td>
</tr>
<tr>
<td>23.2.1</td>
<td>Treatment Allocation by the Manufacturer</td>
<td>276</td>
</tr>
<tr>
<td>23.2.2</td>
<td>The Institutional Pharmacy</td>
<td>276</td>
</tr>
<tr>
<td>23.2.3</td>
<td>Allocation by a Member of the Study Team</td>
<td>277</td>
</tr>
<tr>
<td>23.2.4</td>
<td>Keeping the Randomization Confidential</td>
<td>278</td>
</tr>
<tr>
<td>23.3</td>
<td>Common Problems Maintaining Masking</td>
<td>279</td>
</tr>
<tr>
<td>23.3.1</td>
<td>Side Effects</td>
<td>279</td>
</tr>
<tr>
<td>23.3.2</td>
<td>Efficacy</td>
<td>280</td>
</tr>
<tr>
<td>23.3.3</td>
<td>Leaks and Guesses</td>
<td>281</td>
</tr>
<tr>
<td>23.4</td>
<td>Ethical Issues</td>
<td>281</td>
</tr>
<tr>
<td>Key Points</td>
<td></td>
<td>282</td>
</tr>
<tr>
<td>24.</td>
<td>Adherence and Compliance</td>
<td>284</td>
</tr>
<tr>
<td>24.1</td>
<td>Efficacy versus Effectiveness</td>
<td>284</td>
</tr>
<tr>
<td>24.2</td>
<td>Adherence: How Is It Assessed?</td>
<td>286</td>
</tr>
<tr>
<td>24.3</td>
<td>Overall Measures to Improve Adherence</td>
<td>289</td>
</tr>
<tr>
<td>24.4</td>
<td>Measures to Improve Retention in the Study</td>
<td>292</td>
</tr>
<tr>
<td>24.5</td>
<td>Ethical Issues</td>
<td>293</td>
</tr>
<tr>
<td>Key Points</td>
<td></td>
<td>294</td>
</tr>
<tr>
<td>PART V</td>
<td>ADDITIONAL CONCEPTS FOR OBSERVATIONAL STUDIES</td>
<td>295</td>
</tr>
<tr>
<td>25.</td>
<td>Defining Populations for Cohort Studies</td>
<td>297</td>
</tr>
<tr>
<td>25.1</td>
<td>Data Availability</td>
<td>297</td>
</tr>
<tr>
<td>25.1.1</td>
<td>Data Sources</td>
<td>299</td>
</tr>
<tr>
<td>25.1.2</td>
<td>Stratified Sampling</td>
<td>299</td>
</tr>
<tr>
<td>25.2</td>
<td>Quality of Information</td>
<td>300</td>
</tr>
<tr>
<td>25.3</td>
<td>Study Time Line</td>
<td>302</td>
</tr>
<tr>
<td>25.4</td>
<td>Multiple Cohort Studies</td>
<td>304</td>
</tr>
<tr>
<td>25.5</td>
<td>Ethical Issues</td>
<td>305</td>
</tr>
<tr>
<td>Key Points</td>
<td></td>
<td>306</td>
</tr>
<tr>
<td>26.</td>
<td>Participants in Case-Control Studies</td>
<td>307</td>
</tr>
<tr>
<td>26.1</td>
<td>Identifying Cases and Controls</td>
<td>307</td>
</tr>
<tr>
<td>26.1.1</td>
<td>General Considerations</td>
<td>307</td>
</tr>
<tr>
<td>26.1.2</td>
<td>Identifying Cases</td>
<td>308</td>
</tr>
</tbody>
</table>
Contents

26.1.3 Identifying Controls 311
26.2 Inclusion and Exclusion Criteria for Controls 313
26.3 Special Situations 316
   26.3.1 Multiple Control Groups 316
   26.3.2 Case-Control Studies within Cohort Studies 317
   26.3.3 Historical Controls 317
26.4 Should the Sizes of the Groups Be the Same? 318
26.5 Ethical Issues 319
   Key Points 319

27. Matching in Observational Studies 321
   27.1 Why Match? 321
   27.2 Who Are You Matching? 322
   27.3 When Is Matching Done? 323
   27.4 Individual Matching 325
      27.4.1 Defining Matching Criteria 325
      27.4.2 Choosing between Eligible Controls 327
   27.5 Frequency Matching 328
   27.6 Practical Issues 329
      27.6.1 Overmatching 329
      27.6.2 Excessive Matching Criteria 330
      27.6.3 Special Problems 330
      27.6.4 Data Analysis 332
   27.7 Ethical Issues 332
   Key Points 333

28. Blinding in Observational Studies 334
   28.1 What Can Be Blinded? 334
   28.2 Blinding of Written Records 335
   28.3 Blinding When Assessors Have Contact with Participants 335
   28.4 What to Do When Blinding Is Not Possible 337
   28.5 Ethical Issues 338
   Key Points 339

PART VI  PRACTICAL ISSUES 341

29. Acquiring High Quality Data 343
   29.1 Creating a Study ID 343
   29.2 Methods for Data Collection 344
xvi Contents

29.2.1 Questionnaires 345
29.2.2 Open-Ended Data Collection by an Interviewer 348
29.2.3 Other Types of Procedures Done by Study Staff 351
29.2.4 Tests Done by Non-Study Staff 353
29.3 The Manual of Procedures (MOP) 354
29.4 Ensuring Validity in a Multi-Site Study 354
29.5 Ethical Issues 355
Key Points 356

30. Data Management 358
30.1 Basic Approaches to Data Storage 358
30.2 Documenting the Data 362
   30.2.1 Data Organization and Coding 362
   30.2.2 The Code Book 363
30.3 Selecting a Data Storage Program 364
30.4 Methods of Data Capture 365
30.5 Verifying Data 367
30.6 Preserving Confidentiality 371
30.7 A Note on Programs 373
30.8 Ethical Issues 373
Key Points 374

APPENDIXES STATISTICAL CONCEPTS 375

Appendix A. Hypothesis Testing 377
   A.1 The Criminal Trial as an Analogy for Hypothesis Testing 377
   A.2 Hypothesis Testing 378
   A.3 Determining Statistical Significance 383
   A.4 Clinical Importance 386
   A.5 Ethical Issues 387
Key Points 388

Appendix B. Determining the Sample Size for a Study 390
   B.1 Why Sample Size Matters 390
   B.2 Calculating a ”Just Right Number” 391
| B.3 | The Problem with the “Just Right Number” | 393 |
| B.4 | Legitimate Ways to Reduce the “Just Right Number” | 394 |
| B.5 | The Magical Thinking Way to Reduce the “Just Right Number” | 397 |
| B.6 | An Alternative Way of Thinking about Sample Size | 398 |
| B.7 | Ratio of Sample Sizes between Different Groups | 399 |
| B.8 | Calculating the “Just Right Number” | 400 |
| B.9 | Ethical Issues | 400 |
| Key Points | | 401 |

Index 403
Preface

This book is entitled Planning Clinical Research. We call it “planning” because much of what we do is not the design – in the strict statistical sense – but the overall planning of a study. This includes, of course, the actual design of the study, but planning begins much earlier, with the initial decision: What questions will you ask and how will you ask them? The questions you ask have an impact on the basic design – can you do an interventional study or not? What type of interventional study are you using? Or must you do some type of observational study? But planning a study is much more than choosing the basic design. So even if you have decided on the design (say, a randomized, double-blind, placebo-controlled parallel group study [see Chapter 5 for more about this]), you still need to plan all the details of the study. Who will you be studying? How do you plan to recruit them? How do you plan to retain them in the study? What data do you plan to collect? How will you obtain this data? How will you minimize bias in all aspects of the study? All these decisions must be consistent with the ethics of studying people. This book will help you understand these questions, gain insight into approaches to making these decisions, and understand some of the ethical problems involved in clinical research.

This book is intended to provide the essential concepts and elements of study planning to help you get started. Although we occasionally mention analysis techniques, our focus is on what to do before you have started collecting data. We tried to anticipate the needs of junior investigators who are beginning their research careers, but we hope the book will also be useful for more senior investigators needing to review a specific topic.
To do this, we have used a lot of examples. Often examples are presented multiple times, with refinements or additional information, reflecting how we actually plan a real study. We consider options and keep refining them as we develop the study. We have found that it is best to sketch out options rather than to write out a detailed plan. It seems that once a lot of effort has been put into writing the detailed plan, it becomes an anchor, and making changes to the basic plan becomes very difficult – even when other alternatives are better. We urge you to limit your plan to a single page – preferably a bulleted list – to keep your mind open about possible changes until you really have fully defined the study and have obtained critiques on the idea, so that you are open when a suggestion is made for a radical revision. If you remember nothing else from this book but that you need to always be thinking about refining your design and sharing the plan with your colleagues and (most importantly) actually considering the suggestions they make, we have helped you.

The book is organized in 6 parts containing a total of 30 chapters and 2 appendixes. The organization of the book reflects the basic organization of the research protocol for a study. A study is any systematic investigation intended to answer a question. Since our focus in this book is on clinical research, the questions answered will involve people. However, much of the material, particularly for the design of interventional studies and control of bias, applies to all biological research, whether molecular pathways, cell cultures, or animal studies. The book is not intended to be read cover-to-cover, but rather for you to dip into it as needed.

Clinical studies can only begin after approval by your local Institutional Review Board (IRB), also called an Institutional Ethics Committee (IEC). Thus, Part I of the book (Chapters 1–3) is an introduction to both the fundamental questions you should be asking yourself and ethics and consent issues in clinical research. Some readers may feel that Chapter 1 is quite pretentious. Most statisticians feel that this is the heart of what we do. We discuss ethical issues at length in Chapters 2 and 3. These issues are so fundamental to clinical research that we end each subsequent chapter with a brief discussion of the ethical issues that are relevant to the technical material in the chapter.
The research protocol provides the IRB with the information it needs to decide whether to approve your study. There are many components of the protocol, including the aims of the study, background as to why the study is needed, and the basic study design. Part II of the book (Chapters 4–10) is intended to help you determine the appropriate design for your study. We recommend that all readers read Chapter 4, which provides an overview of all the designs discussed. Then, if you think you are doing an interventional study (meaning that you are doing something to the participants and seeing what happens), you would probably want to go to Chapter 5 for more details of the different types of interventional designs possible. If you are considering an observational study, you would probably want to go to Chapters 6–8, selecting the appropriate one(s) based on the overview material in Chapter 4. We know that many readers may be planning to do record reviews. Although Chapter 9 does discuss this, the chapter—and the design of your record review—will make much more sense to you after reading Chapters 6, 7, or 8, depending on the design used for the record review. Finally, Chapter 10 attempts to synthesize how to select the basic design to be used for your study.

Your protocol also needs details about the participants being studied, the types of data being collected, and how you are intending to control bias. Part III (Chapters 11–18) discusses a number of core concepts that we believe apply across all study designs. These include such basic ideas as generalizability and validity (Chapter 11), practical issues about recruiting and retaining participants (Chapters 12 and 13), the types and uses of data that you will be collecting (Chapters 14–16), and bias and methods to avoid it (Chapters 17 and 18).

Depending on the study design, additional details are needed. Parts IV and V help with these details. Part IV (Chapters 19–24) discusses practical issues relevant to interventional studies, such as how one actually defines the intervention (Chapter 19), how one actually does randomization (Chapters 20 and 21), the hierarchy of blinding and how one does it (Chapters 22 and 23), and how to improve participant adherence (Chapter 24). Part V (Chapters 25–28) discusses the practical issues for observational studies, such as identifying appropriate populations for cohort studies (Chapter 25) or case-control studies including matching (Chapters 26 and 27) and blinding in observational studies (Chapter 28).
Preface

The last part (Chapters 29 and 30) discusses the practical issue of data collection methods and data quality.

Two appendices complete this volume. One discusses the basic ideas behind hypothesis testing, while the second discusses the ideas underlying calculation of an appropriate sample size. A word of warning on this last part of the book: We do not provide formulas, but there are formula in the supplementary material on the book's website (www.cambridge.org/9780521840637) to help you understand sample size calculations and links to appropriate software.

Our examples may reflect real studies we have read, studies planned with colleagues but never done, studies that were completed or may have been completed by the time you read this book, or studies invented solely to make a specific point. We do not include references to any real examples since we have abstracted what we consider the key features illustrating the design point we are trying to make and never present results. Moreover, we often have presented wrong decisions or used hyperbole in the descriptions to help make our point clear.

Of course, just reading a book will not make you an expert in study design or planning. You need to find some mentors – experienced investigators who can help you become a better investigator. We would also recommend that you identify a statistician to work with in developing your study plan.

Given our focus on the ethical aspects of all the topics discussed in the book, although the term “subject” has been used historically for participants in research studies, throughout the book we use terms such as “participant” or “individual” to remind us that the “subjects” are human beings, with their own rights and needs. You never have the right to use, or treat, or think of participants as objects in your research.

To you, our reader, and all your staff and associates, we wish success as a researcher.
Acknowledgments

I thank all the investigators I’ve worked with, and all the students who have taught me so much. It has been a pleasure working with you.

(R.A.P.)

I would like to thank my husband, Arnold Berman, and our children for their encouragement and support as I worked on this book. I also would like to thank the many investigators who I have worked with both in Washington and at the Harbor-UCLA Medical Center for giving me insight into the investigators’ needs in planning clinical studies and providing me with interesting studies to work on.

(N.G.B.)